DOP2018000245A - Proteinas de fusion gdf15 y usos de estas - Google Patents

Proteinas de fusion gdf15 y usos de estas

Info

Publication number
DOP2018000245A
DOP2018000245A DO2018000245A DO2018000245A DOP2018000245A DO P2018000245 A DOP2018000245 A DO P2018000245A DO 2018000245 A DO2018000245 A DO 2018000245A DO 2018000245 A DO2018000245 A DO 2018000245A DO P2018000245 A DOP2018000245 A DO P2018000245A
Authority
DO
Dominican Republic
Prior art keywords
fusion proteins
gdf15 fusion
gdf15
protein
linker
Prior art date
Application number
DO2018000245A
Other languages
English (en)
Inventor
Armstrong Anthony
Ann Connor Judith
Furman Jennifer
Huang Chichi
J Hunger Michael
Lin-Schmidt Xiefan
Serena Nelson
Rangwala Shamina
MULLICAN Shannon
Antonio CHAVEZ Jose
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of DOP2018000245A publication Critical patent/DOP2018000245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se describen proteínas de fusión que contienen una proteína de extensión de vida media, un enlazador y una proteína GDF15. Se describen, además, ácidos nucleicos que codifican las proteínas de fusión, células recombinantes de estos, composiciones que comprenden las proteínas de fusión y métodos para usar las proteínas de fusión para el tratamiento o prevención de enfermedades, trastornos o afecciones metabólicos.
DO2018000245A 2016-05-10 2018-11-09 Proteinas de fusion gdf15 y usos de estas DOP2018000245A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662333886P 2016-05-10 2016-05-10

Publications (1)

Publication Number Publication Date
DOP2018000245A true DOP2018000245A (es) 2019-07-15

Family

ID=60266761

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000245A DOP2018000245A (es) 2016-05-10 2018-11-09 Proteinas de fusion gdf15 y usos de estas

Country Status (27)

Country Link
US (3) US10336812B2 (es)
EP (1) EP3454832A4 (es)
JP (3) JP7022879B2 (es)
KR (2) KR20230169417A (es)
CN (1) CN109451726A (es)
AR (1) AR108442A1 (es)
AU (3) AU2017263237B2 (es)
BR (1) BR112018072946A2 (es)
CA (1) CA3022865A1 (es)
CL (1) CL2018003148A1 (es)
CO (1) CO2018012096A2 (es)
CR (2) CR20180532A (es)
DO (1) DOP2018000245A (es)
EA (1) EA201892561A1 (es)
EC (1) ECSP18083561A (es)
IL (2) IL262652B2 (es)
MA (1) MA44986A (es)
MX (2) MX2018013784A (es)
MY (1) MY191030A (es)
NI (1) NI201800121A (es)
PE (2) PE20190352A1 (es)
PH (1) PH12018502361A1 (es)
SG (2) SG10201912739XA (es)
SV (1) SV2018005781A (es)
TW (1) TWI760333B (es)
WO (1) WO2017196647A1 (es)
ZA (1) ZA201808284B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3763734A1 (en) 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
EP3184106A1 (en) * 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CN109414471A (zh) 2016-05-24 2019-03-01 诺和诺德股份有限公司 Mic-1化合物及其用途
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
US20190224278A1 (en) * 2018-01-22 2019-07-25 Intelligent Synthetic Biology Center Producing method of antimicrobial peptide with enhanced adhesion and uses thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
PE20211078A1 (es) 2018-10-22 2021-06-09 Janssen Pharmaceutica Nv Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas
WO2020084161A1 (en) * 2018-10-26 2020-04-30 Vrije Universiteit Brussel New tools for improving gene therapy and use thereof
WO2020104948A1 (en) * 2018-11-20 2020-05-28 Janssen Pharmaceutica Nv Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake
KR102406899B1 (ko) * 2019-02-27 2022-06-10 주식회사 대웅제약 알부민이 결합된, Slit3 단백질의 LRRD2를 포함하는 근육 질환 예방 또는 치료용 조성물
EP3932430A4 (en) * 2019-02-27 2023-02-01 Daewoong Pharmaceutical Co., Ltd. ALBUMIN-RELATED COMPOSITION COMPRISING LRRD2 OF THE SLIT3 PROTEIN FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
AU2020260931B2 (en) * 2019-04-23 2023-08-24 Lg Chem, Ltd. Fusion polypeptide comprising Fc region of immunoglobulin and GDF15
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
KR20210065057A (ko) * 2019-11-26 2021-06-03 주식회사유한양행 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물
MX2022006634A (es) * 2019-12-11 2022-07-04 Lg Chemical Ltd Polipeptido de fusion que comprende gdf15 y region de polipeptido capaz de experimentar o-glicosilacion.
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
CN111393526B (zh) * 2020-03-30 2022-04-12 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
CN115244076B (zh) * 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
WO2023025129A1 (zh) * 2021-08-24 2023-03-02 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US7919084B2 (en) * 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
PT1641823E (pt) * 2003-06-12 2011-11-08 Lilly Co Eli Proteínas de fusão de análogos de glp-1
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US20120107420A1 (en) * 2008-10-31 2012-05-03 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
TW201101990A (en) 2009-07-08 2011-01-16 zhen-zheng Huang Plant media
NZ597580A (en) * 2009-07-20 2013-11-29 Univ Nat Taiwan Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP2934584B1 (en) * 2012-12-21 2020-02-19 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
HUE039465T2 (hu) * 2013-01-25 2019-01-28 Janssen Biotech Inc KV1.3 antagonisták és alkalmazási eljárások
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP3763734A1 (en) * 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
WO2015198199A1 (en) * 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
KR20170065026A (ko) 2014-07-30 2017-06-12 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애 치료용으로 이용되는 조성물 및 방법
JP6663428B2 (ja) * 2014-10-30 2020-03-11 アクセルロン ファーマ， インコーポレイテッド Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MA46523A (fr) * 2016-10-12 2019-08-21 Janssen Biotech Inc Procédés de criblage de modulateurs d'une activité biologique de type gdf15
PE20211078A1 (es) * 2018-10-22 2021-06-09 Janssen Pharmaceutica Nv Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas

Also Published As

Publication number Publication date
NI201800121A (es) 2019-02-18
WO2017196647A1 (en) 2017-11-16
TWI760333B (zh) 2022-04-11
CL2018003148A1 (es) 2018-12-28
AU2023266233A1 (en) 2023-12-07
JP2022061984A (ja) 2022-04-19
IL262652A (en) 2018-12-31
US11208464B2 (en) 2021-12-28
IL262652B1 (en) 2023-06-01
US20230119382A1 (en) 2023-04-20
SG10201912739XA (en) 2020-02-27
BR112018072946A2 (pt) 2019-02-19
AU2017263237B2 (en) 2021-05-20
CR20230026A (es) 2023-03-13
ZA201808284B (en) 2021-10-27
KR20190003746A (ko) 2019-01-09
SG11201809700YA (en) 2018-11-29
JP2019523637A (ja) 2019-08-29
CA3022865A1 (en) 2017-11-16
AU2017263237A1 (en) 2018-11-22
JP7022879B2 (ja) 2022-02-21
MY191030A (en) 2022-05-29
AU2021218103B2 (en) 2023-08-17
ECSP18083561A (es) 2018-11-30
IL302720A (en) 2023-07-01
MX2024002398A (es) 2024-04-03
JP7481319B2 (ja) 2024-05-10
EP3454832A4 (en) 2019-12-18
CN109451726A (zh) 2019-03-08
KR20230169417A (ko) 2023-12-15
AR108442A1 (es) 2018-08-22
US20170327560A1 (en) 2017-11-16
PH12018502361A1 (en) 2019-09-23
MX2018013784A (es) 2019-03-28
EA201892561A1 (ru) 2019-04-30
IL262652B2 (en) 2023-10-01
US10336812B2 (en) 2019-07-02
AU2021218103A1 (en) 2021-09-09
PE20240015A1 (es) 2024-01-04
TW201803892A (zh) 2018-02-01
EP3454832A1 (en) 2019-03-20
CO2018012096A2 (es) 2018-11-22
MA44986A (fr) 2019-03-20
JP2024102147A (ja) 2024-07-30
US20190292241A1 (en) 2019-09-26
TW202225183A (zh) 2022-07-01
SV2018005781A (es) 2019-03-28
PE20190352A1 (es) 2019-03-07
CR20180532A (es) 2019-03-04

Similar Documents

Publication Publication Date Title
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
CO2018004564A2 (es) Genes de ataxia de friedreich modificados y vectores para terapia génica
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
UY36370A (es) Polipéptidos fgf-21 modificados y sus usos
MX2020003915A (es) Proteinas trispecificas y metodos de uso.
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
MX2021010668A (es) Proteinas de fusion de citoquinas.
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
DOP2016000202A (es) Proteínas de fusión uti
CL2020002650A1 (es) Enzimas quinureninasa humanas y sus usos
CL2015003242A1 (es) Virus aav/upr-plus, proteína de fusión upr-plus, método de tratamiento genético y su uso en el tratamiento enfermedades neurodegenerativas, tales como las enfermedades de parkinson y huntington, entre otras.
CO2020013557A2 (es) Variantes de lfa3 y composiciones y usos de las mismas
AR104475A1 (es) Polipéptidos fgf-21 modificados y sus usos
EA201991181A1 (ru) Psma-нацеленные триспецифические белки и способы их применения
AR106606A1 (es) Genes de ataxia de friedreich modificados y vectores para terapia génica
AR108761A1 (es) Arn modificado que codifica polipéptidos de factor de crecimiento endotelial a (vegf-a), formulaciones y usos relacionados con los mismos
UY36277A (es) Proteínas de fusión uti